Hematologic Oncology

Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.

Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.

Those with relapsed/refractory multiple myeloma and lower tumor burden are also more likely to have deeper responses to idecabtagene vicleucel.

Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.

Psychology intervention service may improve gratitude, anxiety, and physical function when a hematopoietic stem cell transplant is conducted vs standard of care.

Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.

Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.

Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.

Data from the EPCORE NHL-1 trial support the safety and feasibility of epcoritamab for patients with relapsed/refractory follicular lymphoma.

The FDA has approved imetelstat (Rytelo) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring at least 4 red blood cell units over 8 weeks who have not responded to, or have lost response to, or are ineligible for erythropoiesis-stimulating agents.

Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.

The addition of tucidinostat to R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2, according to interim analysis results.

Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.

A reduction in splenomegaly was observed when the combination of pelabresib plus ruxolitinib was used to treat patients with myelofibrosis.

Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.

Efficacy of post-transplant cyclophosphamide vs antithymocyte globulin remains a large discussion for patients with graft-vs-host disease.

ASTCT discusses Richter transformation and treatment options available for this population.

Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.

Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.

A mobile app may help to expedite treatment and identification for patients with GVHD.

One of the most important roles of a nurse coordinator is transmitting patient and caregiver information during the CAR T-cell treatment process.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.